Patents by Inventor Lennart Zabeau

Lennart Zabeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
    Publication number: 20200308244
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Applicant: Orionis Biosciences BV
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • CD8 BINDING AGENTS
    Publication number: 20200231674
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 23, 2020
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • TARGETED ENGINEERED INTERFERON AND USES THEREOF
    Publication number: 20200071414
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: February 5, 2018
    Publication date: March 5, 2020
    Inventors: Nikolai KLEY, Lennart ZABEAU, Jan TAVERNIER
  • TARGETED MUTANT INTERFERON-GAMMA AND USES THEREOF
    Publication number: 20200055912
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 20, 2020
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN, Lennart ZABEAU
  • TARGETING OF CYTOKINE ANTAGONISTS
    Publication number: 20180334489
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: June 14, 2018
    Publication date: November 22, 2018
    Inventors: Jan TAVERNIER, Lennart ZABEAU, Gilles UZE, Franciane PAUL, Yann BORDAT, Genevieve GARCIN
  • TARGETING OF CYTOKINE ANTAGONISTS
    Publication number: 20180334488
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: June 14, 2018
    Publication date: November 22, 2018
    Inventors: Jan TAVERNIER, Lennart ZABEAU, Gilles UZE, Franciane PAUL, Yann BORDAT, Genevieve GARCIN
  • Targeting of human interferon antagonists
    Patent number: 10072059
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 11, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • TARGETING OF CYTOKINE ANTAGONISTS
    Publication number: 20180057555
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: July 6, 2017
    Publication date: March 1, 2018
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Targeting of human interferon antagonists
    Patent number: 9732135
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: August 15, 2017
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Targeting of Cytokine Antagonists
    Publication number: 20160159875
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: July 1, 2014
    Publication date: June 9, 2016
    Inventors: Jan Tavemier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
    Patent number: 7575878
    Abstract: The invention relates to a new type of leptin receptor antagonist, which is able to prevent leptin signaling without preventing the binding of leptin to the leptin binding domain. More specifically, the invention relates to the use of a part of the leptin receptor to prevent the leptin-dependent activation of the receptor, and by this the leptin-induced signaling.
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: August 18, 2009
    Assignees: VIB vzw, Universiteit Gent
    Inventors: Jan Tavernier, Lennart Zabeau
  • Fibronectin III Domain As Leptin Receptor Antagonists
    Publication number: 20070292434
    Abstract: The invention relates to a new type of leptin receptor antagonist, which is able to prevent leptin signaling without preventing the binding of leptin to the leptin binding domain. More specifically, the invention relates to the use of a part of the leptin receptor to prevent the leptin-dependent activation of the receptor, and by this the leptin-induced signaling.
    Type: Application
    Filed: November 16, 2005
    Publication date: December 20, 2007
    Inventors: Jan Tavernier, Lennart Zabeau
  • Functional fragment of the leptin receptor
    Patent number: 7235629
    Abstract: The present invention relates to a functional fragment of a receptor having a function in signaling. Particularly, the present invention relates to a functional fragment of the leptin receptor, involved in SOCS3, CIS and/or Vav signaling.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: June 26, 2007
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Sven Eyckerman, Jan Tavernier, Lennart Zabeau
  • Funtional fragment of the lectine receptor
    Publication number: 20040116340
    Abstract: The present invention relates to a functional fragment of a receptor, important in signaling. Particularly, the present invention relates to a functional fragment of the leptin receptor, involved in SOCS3, CIS and/or Vav signaling.
    Type: Application
    Filed: September 22, 2003
    Publication date: June 17, 2004
    Inventors: Sven Eyckerman, Jan Tavernier, Lennart Zabeau